- Home
- LUCY vs HKPD Comparison
LUCY vs HKPD Comparison
Compare LUCY & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | HKPD |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 10.6M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LUCY | HKPD |
|---|---|---|
| Price | $1.43 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 275.8K | 129.4K |
| Earning Date | 11-13-2025 | 08-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,392,547.00 | ★ $20,313,818.00 |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.22 | 21.72 |
| 52 Week Low | $1.29 | $0.72 |
| 52 Week High | $7.08 | $3.79 |
Technical Indicators
Market Signals| Indicator | LUCY | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 27.59 |
| Support Level | $1.38 | $0.76 |
| Resistance Level | $1.68 | $0.86 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 34.88 | 6.80 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.